Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LEAP-004: initial results

Ana Maria Arance Fernandez, MD, PhD, Hospital Clinic of Barcelona, Barcelona, Spain discusses the initial results from a Phase II trial, LEAP-004 (NCT03776136). This study investigated the use of lenvatinib plus pembrolizumab for advanced melanoma previously treated with a PD-1 or PD-L1 inhibitor. The data reported support lenvatinib plus pembrolizumab as a potential treatment option for this patient population. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

The content of VJOncology is intended for healthcare professionals